Article info
PDFInflammatory bowel disease
Original research
First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn’s disease: an open-label multicentre randomised controlled trial
- Correspondence to Dr Lissy de Ridder, Pediatric Gastroenterology Department, Erasmus MC Sophia Children Hospital, 3000 CA Rotterdam, The Netherlands; l.deridder{at}erasmusmc.nl
Citation
First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn’s disease: an open-label multicentre randomised controlled trial
Publication history
- Received June 25, 2020
- Revised October 15, 2020
- Accepted October 18, 2020
- First published December 31, 2020.
Online issue publication
December 08, 2021
Article Versions
- Previous version (31 December 2020).
- You are viewing the most recent version of this article.
Supplementary Data
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.